Melanoma Cell Line Characterization

Cell line authentication and BRAF/NRAS mutation detection were previously described (8 (link)-10 (link)). Cells were grown in RPMI media in 5% fetal bovine serum. PGC1α promoter reporter was obtained from Addgene. MITF and TRPM1 promoter reporters were obtained from R. Haq (6 (link)). Selumetinib (AZD6244/ARRY142886), AZD8055 and AZD2014 were from AstraZeneca, PLX4720 was from Plexxikon, and other inhibitors were from SelleckChem. For in vitro treatments, the inhibitors were dissolved in DMSO.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Gopal Y.N., Rizos H., Chen G., Deng W., Frederick D.T., Cooper Z.A., Scolyer R.A., Pupo G., Komurov K., Sehgal V., Zhang J., Patel L., Pereira C.G., Broom B.M., Mills G.B., Ram P., Smith P.D., Wargo J.A., Long G.V, & Davies M.A. (2014). Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and Oxidative Phosphorylation in melanoma. Cancer research, 74(23), 7037-7047.

Publication 2014

AZD2014 PLX4720

Arry142886 Azd2014 Azd6244 Azd8055 Braf Cell line authentication Cells Dmso Fetal bovine serum Inhibitors Mitf Mutation Nras Pgc1α Plx4720 Selumetinib

Corresponding Organization : The University of Texas MD Anderson Cancer Center

Other organizations : Melanoma Institute Australia, Westmead Hospital, Massachusetts General Hospital, University of Cincinnati, AstraZeneca (United Kingdom)

Top 5 similar protocols

Protocol cited in 3 other protocols

Variable analysis

independent variables

Selumetinib (AZD6244/ARRY142886)
AZD8055
AZD2014
PLX4720

dependent variables

Cell line authentication
BRAF/NRAS mutation detection
PGC1α promoter reporter activity
MITF promoter reporter activity
TRPM1 promoter reporter activity

control variables

Cells were grown in RPMI media in 5% fetal bovine serum

controls

No positive or negative controls were explicitly mentioned.

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!